Bill

A 2725

Requires employers to include an opioid antagonist where first aid kits are required by federal law

2025 Regular Session Introduced by William Colton and 3 co-sponsors

Requires employers with federally mandated first-aid kits to include an opioid antagonist (e.g., naloxone), enabling on-site responders to treat overdoses.

RETURNED TO ASSEMBLY

WeVote Research Nonpartisan

Bill Summary · A 2725

Summary: Assembly Bill A 2725 (Opioid Antagonist in Required First Aid Kits)

Overview and Purpose

Bill A 2725 would require employers to include an opioid antagonist in first aid kits in situations where such kits are mandated by federal law. The underlying intent is to improve workplace readiness to respond to opioid overdoses by ensuring access to a reversible opioid overdose treatment (e.g., naloxone) in on-site first aid responders or others trained to use the kit.

Key Provisions (as described)

Mandate: Employers must place an opioid antagonist inside first aid kits whenever federal law requires the presence of first aid kits at a workplace.
Scope: Applies to workplaces governed by federal first aid kit requirements (exact regulatory scope would be defined in the bill’s text).

Note: The provided materials do not include the full statutory text, so specific provisions such as training requirements, storage standards, expiration date management, signage, liability protections, or enforcement mechanisms are not itemized here. The bill’s version A2725A exists, but detailed language is not provided in the supplied materials.

Affected Parties and Impact

Primarily employers subject to federal first aid kit requirements.
Employees and on-site responders who would potentially use an opioid antagonist in emergencies.
Stakeholders may consider costs of procurement, ongoing stock management, and potential training implications.

Legislative Status and Timeline

Introduced: January 22, 2025
Initial referral: January 22, 2025 (to Labor)
Amendments: Printing as 2725A and amendments on April 22, 2025
Assembly actions: Advanced to third reading CAL.111 on May 1, 2025; delivered to Senate May 5, 2025; passed Assembly May 5, 2025
Senate actions: Referred to related committee; passed Senate on June 6, 2025
Substitution/Approval: On June 6, 2025, substituted for S 5922A; status returned to Assembly
Current status: RETURNED TO ASSEMBLY
Related bill: S 5922 (companion)

Related Legislation

Companion bill: S 5922 (same or substantially similar proposal)

Practical Considerations and Next Steps

If the Assembly approves the substituted bill, it would proceed toward enactment and, depending on procedural steps, could be transmitted to the governor for signature or veto.
Potential considerations for stakeholders include cost implications for employers, the need for training or protocols around administration of an opioid antagonist, and any liability or regulatory clarifications.

This summary captures the bill’s stated purpose, the high-level anticipated impact, the legislative trajectory, and key sponsorship details based on the materials provided.

Compiled from official sources — confirm details with the bill’s official record.